German Adjuvant Intergroup Node-positive Study (GAIN): A Phase III Trial Comparing Two Dose-Dense Regimens (iddEPC vs. ddEC-PwX) in High-Risk Early Breast Cancer Patients. - Wikidata - awgldk - TriplyDB

German Adjuvant Intergroup Node-positive Study (GAIN): A Phase III Trial Comparing Two Dose-Dense Regimens (iddEPC vs. ddEC-PwX) in High-Risk Early Breast Cancer Patients.

German Adjuvant Intergroup Node-positive Study (GAIN): A Phase III Trial Comparing Two Dose-Dense Regimens (iddEPC vs. ddEC-PwX) in High-Risk Early Breast Cancer Patients.

http://www.wikidata.org/entity/Q30313214

about

Dose intense, dose dense and tailored dose adjuvant chemotherapy for early breast cancer: an evolution of concepts.

P2860

Q36379148-36657D80-9417-4038-854C-CF33088BAC1F

P2860

German Adjuvant Intergroup Node-positive Study (GAIN): A Phase III Trial Comparing Two Dose-Dense Regimens (iddEPC vs. ddEC-PwX) in High-Risk Early Breast Cancer Patients.

http://www.wikidata.org/entity/Q30313214

description

2017 nî lūn-bûn

@nan

2017 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

German Adjuvant Intergroup Nod ...... Early Breast Cancer Patients.

@ast

German Adjuvant Intergroup Nod ...... Early Breast Cancer Patients.

@en

type

label

German Adjuvant Intergroup Nod ...... Early Breast Cancer Patients.

@ast

German Adjuvant Intergroup Nod ...... Early Breast Cancer Patients.

@en

prefLabel

German Adjuvant Intergroup Nod ...... Early Breast Cancer Patients.

@ast

German Adjuvant Intergroup Nod ...... Early Breast Cancer Patients.

@en

P1433

Q30313214-2BE9624E-3A7B-42A5-9EAD-5C38261BE764

P1476

Q30313214-89CC6EB1-DA62-43B6-BDB5-432622F5BA0F

P2093

Q30313214-004DCD83-1B11-470F-8C6D-6677D2FD8BDF

Q30313214-08354B20-9FF1-4051-91DD-EAD508F742FA

Q30313214-1390F03B-DCF7-4F41-AA27-8B8566CAE430

Q30313214-1C2042A4-1FA0-4841-A7DC-ECCC07F87F93

Q30313214-212BCAA0-8826-4883-AC8C-E969D44FDDE2

Q30313214-2CAFE7E7-82CC-4B16-A3B0-67C443963114

Q30313214-2D7FDF08-FFF0-4C2D-B060-DC3AD702388C

Q30313214-30A64F77-3A1C-46BC-A2FD-FDCF7CA94245

Q30313214-419080A4-9843-4E80-BE61-3A33B66BA3BA

Q30313214-5706FFCB-4313-4557-82B2-955A61504713

P2860

Q30313214-0AA21B84-D644-4405-8673-0D1102996343

Q30313214-12E2FAD7-010D-4589-8C03-82AAF4F536DF

Q30313214-3FBC8D32-A61D-4D46-B0E0-AF97A6F961DE

Q30313214-40129F69-0F46-43EF-BD60-1CCBFB6CADAF

Q30313214-44A2F9A6-62C6-4E23-821F-3A999B878732

Q30313214-4F5F3131-6101-48DD-931D-7CB9D6EB33B7

Q30313214-506D97DC-8D3D-44F0-BA9B-0C13E1B0E974

Q30313214-716BD91B-D1D9-4E74-B2E1-CDC5BE61DDE7

Q30313214-7DA226C5-9A77-481B-B244-20C899A94A31

Q30313214-9D8D6CD3-6CEE-45C7-BCA3-3AC4A6F3165B

P31

Q30313214-510CBCEB-C068-43D8-A477-9BAE3062FAB8

P356

Q30313214-ABE49601-8E02-4F01-9DBF-7CEDBCC2F856

P50

Q30313214-4A56E533-276E-40A8-B125-6DA191F3FBC2

Q30313214-A5FEDF79-4051-4236-A45B-5DB122C7AF00

Q30313214-BC451E41-3579-4485-B81D-5E644EA32DDA

P577

Q30313214-5DD1A633-5D10-4BC4-9579-A37B6093D02B

P698

Q30313214-AE301C75-C735-468F-BC03-2BB6732D3093

P921

Q30313214-4A84C01B-71F0-40FC-A9FA-CFAC64FE3BB4

P356

P1433

Annals of Oncology

P1476

German Adjuvant Intergroup Nod ...... Early Breast Cancer Patients.

@en

P2093

A du Bois

http://www.w3.org/2001/XMLSchema#string

B Conrad

http://www.w3.org/2001/XMLSchema#string

C Jackisch

http://www.w3.org/2001/XMLSchema#string

C Thomssen

http://www.w3.org/2001/XMLSchema#string

D Elling

http://www.w3.org/2001/XMLSchema#string

G von Minckwitz

http://www.w3.org/2001/XMLSchema#string

German Breast Group (GBG),the AGO Breast Study Group (AGO-B) and NOGGO study groups

http://www.w3.org/2001/XMLSchema#string

H Tesch

http://www.w3.org/2001/XMLSchema#string

H-J Lück

http://www.w3.org/2001/XMLSchema#string

I Bauerfeind

http://www.w3.org/2001/XMLSchema#string

P2860

A multiple testing procedure for clinical trials

Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study.

Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials.

First efficacy results of capecitabine with anthracycline- and taxane-based adjuvant therapy in high-risk early breast cancer: a meta-analysis

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.

Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial.

Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.

Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.

Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial.

Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33).

P31

scholarly article

P356

10.1093/ANNONC/MDX203

http://www.w3.org/2001/XMLSchema#string

P50

Andreas Schneeweiss

P577

2017-04-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28459941

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial